Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

New preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune “death receptor,” and statistically significant downregulation of HLA-G, an established immune checkpoint, in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines representing three distinct KRAS mutations (G12D, G12V, and G12C)

Combined with previously reported MHC-I upregulation, findings support a coordinated immune-sensitization signature across three key immune pathways - increased antigen presentation, restored susceptibility to immune-mediated apoptosis, and reduced immune checkpoint activity - and reinforce the scientific rationale for combining SIL204 with anti-PD-(L)1 immune checkpoint inhibitor therapies